Floatz logo

Raltegravir

Solid Tumor

National University Hospital, SingaporeSmall moleculePhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
59/ 100

Competitive context

480 Active assets in the Solid Tumor cohort.

Asset / SponsorPhaseRating
Irinotecan
Mirati Therapeutics Inc.
Phase 4BB
(+)-VINCRISTINE
Pfizer
Phase 4B
Atezolizumab
Hoffmann-La Roche
Phase 2/3B
Durvalumab
GlaxoSmithKline
Phase 4B
Rivoceranib
Beidahuang Industry Group General Hospital
Phase 3B

View all 50 →

Same molecule, other indications

Raltegravir is also rated in:

HIV infectious diseaseDormant
A
Indicative ·
80 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
68 / 100
View asset →
osteoporosisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →